**Core Concept**
The MARINA trial is a landmark study investigating the efficacy of a specific treatment modality for a particular ocular condition. It aims to evaluate the outcomes of a particular intervention on the progression of the disease.

**Why the Correct Answer is Right**
The MARINA trial was designed to assess the safety and efficacy of ranibizumab, an anti-vascular endothelial growth factor (VEGF) agent, in patients with neovascular (wet) age-related macular degeneration (AMD). Ranibizumab works by inhibiting the activity of VEGF, a protein that promotes angiogenesis and contributes to the pathogenesis of neovascular AMD. By reducing VEGF activity, ranibizumab helps to decrease the formation of new blood vessels and subsequent vision loss.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the MARINA trial did not focus on the use of laser photocoagulation, a traditional treatment for neovascular AMD.
**Option B:** This option is incorrect because the MARINA trial did not investigate the use of corticosteroids, which are not typically used as first-line treatment for neovascular AMD.
**Option C:** This option is incorrect because the MARINA trial did not evaluate the effectiveness of a different anti-VEGF agent, such as bevacizumab or pegaptanib.

**Clinical Pearl / High-Yield Fact**
The MARINA trial highlights the importance of anti-VEGF therapy in the management of neovascular AMD, demonstrating significant improvements in visual acuity and reduction in the risk of vision loss. This finding has led to widespread adoption of anti-VEGF agents as a first-line treatment for this condition.

**Correct Answer: D. Evaluating the efficacy of ranibizumab in neovascular age-related macular degeneration.**